DRA02 - A PHASE 1 STUDY EVALUATING THE SAFETY AND PRELIMINARY EFFICACY OF ALLO-329, A DUAL ANTI-CD19 / ANTI-CD70 ALLOGENEIC CAR T CELL PRODUCT IN AUTOIMMUNE DISEASE (RESOLUTION)
Clinical Trial Grant
Awarded By
Allogene Therapeutics, Inc.
Start Date
July 2, 2025
End Date
July 6, 2035
Awarded By
Allogene Therapeutics, Inc.
Start Date
July 2, 2025
End Date
July 6, 2035